Merck & Co., Inc. (MRK)
Why Merck (MRK) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Merck: Fundamentals Amplified By A Momentum Breakout
Merck has surged nearly 30% since my prior bullish call, reflecting strong share price momentum. MRK fundamentals are robust, underpinned by stellar financial performance and promising regulatory developments. Valuation remains highly attractive, with improving market sentiment supporting continued upside.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Merck (MRK) Laps the Stock Market: Here's Why
The latest trading day saw Merck (MRK) settling at $106.45, representing a +1.13% change from its previous close.
Merck: A Pharma Giant Trading At A Decade-Low Valuation While Executing Its Post-Keytruda Playbook
Merck & Co. trades at a deep discount, reflecting market fears over the 2028 Keytruda patent cliff despite robust Q3 2025 results and pipeline momentum. MRK's diversification strategy is gaining traction: Winrevair's rapid ramp to nearly $1B, Capvaxive's $2B+ potential, and subcutaneous Keytruda QLEX extending exclusivity beyond 2028. Financial strength underpins the transition: $17.1B TTM operating cash flow, $18.2B cash, 15-year dividend growth streak, and sector-leading profitability metrics.
Merck: Framework For Success
Merck is rated a buy, with strong earnings growth, rising cash flow, and balance sheet strength supporting a bullish outlook. Keytruda's double-digit growth and margin expansion drive MRK's profits, but future exclusivity loss in 2028 is a material risk. The company trades at a significant discount—13.8x forward PE, the lowest among peers—while showing the best YoY EBITDA growth and a PEG of 1.23.
Merck: A Post-2028 Slowdown Doesn't Kill The Long-Term Thesis
Merck earns a cautious "Buy" rating due to an intriguing valuation and clear, somewhat manageable uncertainties, especially post-Keytruda expiry in 2028. MRK's heavy reliance on Keytruda poses risk, but Animal Health growth, pipeline depth, and margin strength offer diversification and optionality. Even in conservative scenarios, MRK could deliver ~7% annualized returns, with potential for double-digit upside if new drugs succeed and margins improve.
Why Merck (MRK) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Merck (MRK) Outpaced the Stock Market Today
The latest trading day saw Merck (MRK) settling at $106.45, representing a +1.34% change from its previous close.
Wall Street Analysts Think Merck (MRK) Is a Good Investment: Is It?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
US FDA grants priority vouchers to Merck's cholesterol pill, cancer therapy
The U.S. Food and Drug Administration said on Friday it has granted national priority vouchers to Merck's cholesterol pill and its cancer therapy, making them the latest additions to the fast-track program.
